Acepodia Biotech, Inc.: Phase 1 study in Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic (70 participants)
Acepodia Biotech, Inc.: Phase 1 study in Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic (70 participants). Its enrollment of 70 is below the median of 80 (46th percentile). Dated 30 days ago, it is in the active follow-up window. Score 50/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 70 · 46th percentile of 8,879 ClinicalTrialStartPulse records · 0.9x the median
Free preview: all 14 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Acepodia Biotech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs |
| NCT ID | NCT07861425 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Hepatocellular Carcinoma (HCC); Hepatocellular Carcinoma Metastatic; Hepatocellular Carcinoma Non-Resectable |
| Intervention types | drug |
| Target enrollment | 70 |
| Site countries | China |
| Posted | 2026-10-06 |
| Planned start | 2026-11 |
| Event | Newly registered study |
| Event date | 2026-10-06 |
| enrollment percentile | 46th of 8,879 (median 80, 0.9x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Acepodia Biotech, Inc.
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Acepodia Biotech + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-06
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Acepodia Biotech, Inc. and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Acepodia Biotech, Inc.'s enrollment: 46th percentile of 8,879 records
- Timing: Medium: dated in the last 30 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
50 / 100 Score
- Industry sponsor (buys outsourced services).
- Not yet recruiting: vendors still being chosen.
What is the ClinicalTrialStartPulse record for Acepodia Biotech, Inc.?
Acepodia Biotech, Inc. registered a Phase 1 study (NCT07861425) in Hepatocellular Carcinoma (HCC) targeting 70 participants, posted 2026-10-06.
How does Acepodia Biotech, Inc. compare to other ClinicalTrialStartPulse records?
Its enrollment of 70 is below the median (46th percentile); smaller records often move faster and face less competition. It is 30 days old, still within a typical 45-day follow-up window.
Acepodia Biotech, Inc. vs. top 2 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Acepodia Biotech, Inc. | NONUS | 70 | 46th | 2026-10-06 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | NONUS | 270 | 81st | 2026-11-03 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | NONUS | 420 | 88th | 2026-10-28 |
Related records
- Hoffmann-La Roche
- MacroGenics
- Mabsoft Therapeutics (Shanghai) Co., Ltd.
- Sutro Biopharma, Inc.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Janssen Research & Development, LLC
- Janssen Research & Development, LLC
- Genentech, Inc.
ClinicalTrialStartPulse: Phase 1 ClinicalTrialStartPulse: Outside the US only
How to monitor Acepodia Biotech, Inc. and peer phase 1 records
Get new ClinicalTrialStartPulse records like Acepodia Biotech, Inc. by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.